Beam Therapeutics (BEAM) Stock Price, News & Analysis

Company Overview

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $32.00 to $33.91
• 50-Day Range: $23.30 to $34.16
• 52-Week Range: $20.84 to $49.50
• Volume: 237,779 shs
• Average Volume: 1.21 million shs
• Market Capitalization: $2.67 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.67
• Consensus Rating: Buy

Beam Therapeutics Stock Analysis - MarketRank™

Beam Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 351st out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Beam Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Beam Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beam Therapeutics are expected to grow in the coming year, from ($4.57) to ($4.27) per share.

Price to Book Value per Share Ratio

Beam Therapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.10% of the outstanding shares of Beam Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Beam Therapeutics has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beam Therapeutics does not currently pay a dividend.

Dividend Growth

Beam Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.10% of the outstanding shares of Beam Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Beam Therapeutics has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 0.97

News Sentiment

Beam Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.

Search Interest

9 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

9 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $833,128.00 in company stock.

Percentage Held by Insiders

Only 4.20% of the stock of Beam Therapeutics is held by insiders.

Percentage Held by Institutions

99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BEAM Stock Analysis - Frequently Asked Questions

How have BEAM shares performed this year?

Beam Therapeutics' stock was trading at $24.80 on January 1st, 2025. Since then, BEAM shares have increased by 33.6% and is now trading at $33.14.
View the best growth stocks for 2025 here.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.01. Beam Therapeutics's quarterly revenue was down 16.9% on a year-over-year basis.

Does Beam Therapeutics have any subsidiaries?

Beam Therapeutics subsidiaries include these companies: Blink Therapeutics Inc..

When did Beam Therapeutics IPO?

Beam Therapeutics (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' top institutional investors include Farallon Capital Management LLC (9.95%), Vanguard Group Inc. (9.20%), ARK Investment Management LLC (8.54%) and ARCH Venture Management LLC (5.48%). Insiders that own company stock include Fmr Llc, John M Evans, Giuseppe Ciaramella, Christine Bellon, Terry-Ann Burrell, Amy Simon and Bethany J Cavanagh.
View institutional ownership trends.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BEAM
• CUSIP: N/A
• CIK: 1745999
• Web: www.beamtx.com
• Phone: 857-327-8775
• Fax: N/A
• Employees: 510
• Year Founded: 2017

Price Target and Rating

• Average Stock Price Target: $47.67
• High Stock Price Target: $80.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +43.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-132,530,000.00
• Net Margins: -41.07%
• Pretax Margin: -40.67%
• Return on Equity: -16.22%
• Return on Assets: -10.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: 5.69

Sales & Book Value

• Annual Sales: $377.71 million
• Price / Sales: 7.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.04 per share
• Price / Book: 2.75

Miscellaneous

• Outstanding Shares: 82,810,000
• Free Float: 79,328,000
• Market Cap: $2.74 billion
• Optionable: Optionable
• Beta: 1.92